## **URINE CYTOLOGY**

LEAH DVORAK M.D.

ANATOMIC AND CLINICAL PATHOLOGIST

MINNESOTA PATHOLOGISTS CHARTERED

MAY 2024


# PURPOSE OF URINE CYTOLOGY AND WHEN TO ORDER

- Purpose:
  - To detect urothelial carcinoma.
- When to order:
  - GROSS HEMATURIA
    - 85% of patients with a new bladder tumor present with gross hematuria
    - Microscopic hematuria has a low predictive value for bladder cancer
  - Urinary frequency, urgency, difficulty urinating, dysuria
    - Bladder cancer can present with UTI symptoms

#### TYPES OF CANCER IN THE BLADDER

- UROTHELIAL CARCINOMA (90%)
  - Low-grade
    - Low-grade papillary urothelial carcinoma
      - Noninvasive and invasive
  - High grade
    - Flat urothelial carcinoma in situ
    - High-grade papillary urothelial carcinoma
      - · Noninvasive and invasive
- Others
  - Squamous cell carcinoma, adenocarcinoma, small cell carcinoma, sarcoma, lymphoma, melanoma, direct extension of tumor outside the bladder

#### Bladder cancer - more then one disease?




- ~ 75 % Non-Muscle-Invasive (Ta/T1)
  - Good prognosis
  - Recurrence
  - 10%-15% progression (LG Ta - <1%)\*</p>
- ~ 25 % Muscle-Invasive
   (≥ T2)
  - >60% overall survival

<sup>\*</sup>Nielsen ME et al. Trends in Stage-Specific Incidence Rates for Urothelial Carcinoma of the Bladder In the United States: 1998-2006. Cancer 2014:120:86

# SENSITIVITY OF URINE CYTOLOGY FOR DIAGNOSING UROTHELIAL CARCINOMA

- Not good for the diagnosis of low-grade urothelial carcinoma (10-20%)
- Quite good for the diagnosis of high-grade urothelial carcinoma (>95%)
- High-grade urothelial carcinoma is what we really care about
  - Potential for deep muscle invasion, metastasis and death



## **Clinical Management**


Marcus L. Quek, Trinity J. Bivalacqua, Ashish M. Kamat, and Mark P. Schoenberg

#### Risk of malignancy – ongoing studies

Category	Risk of Malignancy	Management
Unsatisfactory/Nondiagnostic	? (<5%)	Repeat cytology, cystoscopy in 3 months if increased clinical suspicion
Negative for HGUC	0-2%	Clinical follow up as needed
Atypical Urothelial Cells (AUC)	8-35%	Clinical follow up as needed. Use of ancillary testing.
Suspicious for HGUC	50-90%	More aggressive follow up, cystoscopy, biopsy
LGUN	~10%	Need biopsy to further evaluate grade and stage
High Grade UC	>90%	More aggressive follow up, cystoscopy, biopsy, staging
Other malignancy	>90%	More aggressive follow up, cystoscopy, biopsy, staging

# MANAGEMENT OPTIONS FOR AUC

- Clinical judgement
  - · Low risk:
    - No other cause for atypia => repeat urine cytology in 3 months
    - Other cause for atypia => Nothing
  - · High risk:
    - Ancillary testing
      - UroVysion FISH (sensitivity 89% for AUC)
    - · Repeat urine cytology
    - Cystoscopy



https://www.slideshare.net/slideshow/urothelial-ca-urinary-mark ers/49680032

# EFFECTIVENESS OF UROVYSION FISH AND CYTOLOGY FOR BLADDER CANCER DETECTION

	Sensitivity	Specificity
Urovysion FISH	72% 89% (with a cytology dx of AUC)	83%
Cytology	42%	96%



## URINE CYTOLOGY CYTOSPIN PROCEDURE



**KNOW WHAT'S GOING ON!** 

### To claim CME credit (Must complete by 12-27-2024)



- Scan QR Code or click on the link below-
- iPhone: use camera to take you to the site
- QR Code Reader App
- Snap Chat (take a snap!)
- Facebook ("Explore" QR Code)

https://survey.alchemer.com/s3/7645302/CME -Clinical-Updates-ENDURING-MATERIAL

 Contact <u>carla.griffin@centracare.com</u> with questions or for a CME transcript.